We will review all available studies on the use of lacosamide in the treatment of partial-onset seizures. The available evidence includes two open-label studies and three randomized controlled trials evaluating the safety and efficacy of oral lacosamide. One open-label study and one randomized controlled trial evaluating the safety and tolerability of intravenous lacosamide was also identified. Lacosamide was found to be efficacious with significant reduction in seizure frequency dosed 400-600 mg daily. Moreover, its adverse drug effects were mild and infrequently reported in the literature. Findings suggest that lacosamide is an effective agent for adjunctive treatment of refractory partial-onset seizures.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6493858 | PMC |
| http://dx.doi.org/10.1111/j.1755-5949.2010.00198.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Monitoring Addiction to Pregabalin in Northern Algeria by Using Hair Testing.
Electrophoresis
December 2024
Unit of Forensic Medicine, Department of Diagnostics and Public Health, University of Verona, Verona, Italy.
Pregabalin (PGB) is a novel gamma-aminobutyric acid analog that has been recently approved for the treatment of partial-onset seizures, neuropathic pain, and fibromyalgia. Although PGB presents a low potential for abuse in comparison to other scheduled drugs, the literature reports its potential misuse, especially among individuals with former or current drug addiction. The present study aimed to develop and validate a novel method for the determination of PGB in hair to perform a retrospective observational study on the misuse of this drug in a population of addicted subjects from Northern Algeria.
View Article and Find Full Text PDFA multicenter, cross-sectional analysis to assess the safety and usage pattern of brivaracetam in the management of partial-onset seizure with BAEs-BREEZE study: A post-hoc analysis.
Epilepsia Open
November 2024
Medical Affairs, Torrent Pharmaceuticals Ltd, Ahmedabad, Gujarat, India.
Objective: Brivaracetam (BRV), a third-generation anti-seizure medication (ASM) offers strong conformational receptor domain binding, faster blood brain barrier (BBB) permeability and better tolerability making it potential therapeutic option as an initial line or initial line add-on strategy for focal onset seizure (FoS). The following study was planned to further understand the role and relevance of BRV in the real world settings of India.
Method: This was a multicentric, cross-sectional, and non-interventional study conducted in patients with FoS across India.
A real-world pharmacovigilance analysis of eslicarbazepine acetate using the FDA adverse events reporting system (FAERS) database from 2013 (Q4) to 2024 (Q1).
Front Pharmacol
September 2024
Department of Pharmacy, The 305 Hospital of PLA, Beijing, China.
Article Synopsis
- The study investigates adverse events (AEs) associated with eslicarbazepine acetate (ESL), a medication approved in 2013 for partial-onset seizures, using data from the FDA Adverse Event Reporting System (FAERS).
- It employs various statistical methods to identify significant AE signals and examines demographic factors like gender and age related to these events.
- The analysis revealed 5,719 AE reports, with notable issues related to nervous system disorders occurring mostly within the first month of treatment, resulting in 86 significant positive signals.
Respiratory Acidosis as a Diagnostic Clue in Symptomatic Epilepsy With Stroke Mimics: A Case Report.
Cureus
June 2024
Department of Emergency Medicine, Fukuoka Kinen Hospital, Fukuoka, JPN.
Stroke mimics are difficult to differentiate from each other. Symptomatic epilepsy can also occur, but it is necessary to perform a magnetic resonance imaging (MRI) scan to distinguish it from a stroke. Although respiratory acidosis has been reported to occur with partial-onset seizures due to prolonged apnea, respiratory acidosis is rarely suspected to be a sign of epilepsy.
View Article and Find Full Text PDFCircumscribing Laser Cuts Attenuate Seizure Propagation in a Mouse Model of Focal Epilepsy.
Adv Sci (Weinh)
August 2024
Meinig School of Biomedical Engineering, Cornell University, Ithaca, NY, 14853, USA.
Article Synopsis
- In partial onset epilepsy, seizures start in specific brain areas and can become resistant to medication, making neurosurgery a key treatment option that risks neurological deficits.
- A study on mice with focal neocortical epilepsy applied precise cuts using femtosecond laser pulses around the seizure focus, significantly reducing seizure frequency by 87% and limiting the spread of seizures.
- The surgical cuts led to minimal collateral damage and did not impair motor skills in reaching tasks, indicating potential for this method as an effective neurosurgical strategy for treating refractory focal epilepsy.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!